Skip to main content
NYSE:CRL

Charles River Laboratories International Competitors

$316.76
-3.74 (-1.17 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$315.42
$331.99
50-Day Range
$276.21
$345.21
52-Week Range
$157.39
$349.13
Volume730,983 shs
Average Volume341,963 shs
Market Capitalization$15.92 billion
P/E Ratio52.79
Dividend YieldN/A
Beta1.12

Competitors

Charles River Laboratories International (NYSE:CRL) Vs. TMO, ILMN, A, MTD, WAT, and BIO

Should you be buying CRL stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Charles River Laboratories International, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), and Bio-Rad Laboratories (BIO).

Thermo Fisher Scientific (NYSE:TMO) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Volatility & Risk

Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Insider & Institutional Ownership

87.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 92.3% of Charles River Laboratories International shares are held by institutional investors. 0.4% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 1.9% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Thermo Fisher Scientific and Charles River Laboratories International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific17.12%21.35%10.55%
Charles River Laboratories International10.68%22.41%7.66%

Valuation and Earnings

This table compares Thermo Fisher Scientific and Charles River Laboratories International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion7.00$3.70 billion$12.3536.82
Charles River Laboratories International$2.62 billion6.07$252.02 million$6.7347.07

Thermo Fisher Scientific has higher revenue and earnings than Charles River Laboratories International. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Thermo Fisher Scientific and Charles River Laboratories International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific021802.90
Charles River Laboratories International03902.75

Thermo Fisher Scientific presently has a consensus target price of $536.8947, suggesting a potential upside of 18.06%. Charles River Laboratories International has a consensus target price of $286.4167, suggesting a potential downside of 9.58%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, research analysts clearly believe Thermo Fisher Scientific is more favorable than Charles River Laboratories International.

Summary

Thermo Fisher Scientific beats Charles River Laboratories International on 9 of the 14 factors compared between the two stocks.

Illumina (NASDAQ:ILMN) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Volatility & Risk

Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Illumina and Charles River Laboratories International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Illumina47602.12
Charles River Laboratories International03902.75

Illumina presently has a consensus target price of $374.50, suggesting a potential upside of 0.45%. Charles River Laboratories International has a consensus target price of $286.4167, suggesting a potential downside of 9.58%. Given Illumina's higher probable upside, research analysts clearly believe Illumina is more favorable than Charles River Laboratories International.

Profitability

This table compares Illumina and Charles River Laboratories International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Illumina19.70%15.93%10.09%
Charles River Laboratories International10.68%22.41%7.66%

Insider & Institutional Ownership

90.0% of Illumina shares are held by institutional investors. Comparatively, 92.3% of Charles River Laboratories International shares are held by institutional investors. 0.4% of Illumina shares are held by insiders. Comparatively, 1.9% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Illumina and Charles River Laboratories International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$3.54 billion15.36$1.00 billion$6.5756.75
Charles River Laboratories International$2.62 billion6.07$252.02 million$6.7347.07

Illumina has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Charles River Laboratories International on 8 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and Agilent Technologies (NYSE:A) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Charles River Laboratories International and Agilent Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International03902.75
Agilent Technologies061902.76

Charles River Laboratories International presently has a consensus price target of $286.4167, indicating a potential downside of 9.58%. Agilent Technologies has a consensus price target of $107.4350, indicating a potential downside of 16.48%. Given Charles River Laboratories International's higher probable upside, equities analysts plainly believe Charles River Laboratories International is more favorable than Agilent Technologies.

Profitability

This table compares Charles River Laboratories International and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories International10.68%22.41%7.66%
Agilent Technologies13.47%21.02%10.73%

Insider and Institutional Ownership

92.3% of Charles River Laboratories International shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Charles River Laboratories International and Agilent Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$2.62 billion6.07$252.02 million$6.7347.07
Agilent Technologies$5.34 billion7.34$719 million$3.2839.22

Agilent Technologies has higher revenue and earnings than Charles River Laboratories International. Agilent Technologies is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats Charles River Laboratories International on 8 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and Mettler-Toledo International (NYSE:MTD) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Charles River Laboratories International and Mettler-Toledo International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International03902.75
Mettler-Toledo International23101.83

Charles River Laboratories International presently has a consensus price target of $286.4167, indicating a potential downside of 9.58%. Mettler-Toledo International has a consensus price target of $1,048.3333, indicating a potential downside of 15.56%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, equities analysts plainly believe Charles River Laboratories International is more favorable than Mettler-Toledo International.

Profitability

This table compares Charles River Laboratories International and Mettler-Toledo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories International10.68%22.41%7.66%
Mettler-Toledo International19.36%144.89%21.11%

Insider and Institutional Ownership

92.3% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 93.2% of Mettler-Toledo International shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by insiders. Comparatively, 3.2% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Charles River Laboratories International and Mettler-Toledo International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$2.62 billion6.07$252.02 million$6.7347.07
Mettler-Toledo International$3.01 billion9.60$561.11 million$22.7754.52

Mettler-Toledo International has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Summary

Mettler-Toledo International beats Charles River Laboratories International on 9 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and Waters (NYSE:WAT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Charles River Laboratories International and Waters, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International03902.75
Waters37101.82

Charles River Laboratories International presently has a consensus price target of $286.4167, indicating a potential downside of 9.58%. Waters has a consensus price target of $251.25, indicating a potential downside of 17.25%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, equities analysts plainly believe Charles River Laboratories International is more favorable than Waters.

Profitability

This table compares Charles River Laboratories International and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories International10.68%22.41%7.66%
Waters22.61%-349.31%21.11%

Insider and Institutional Ownership

92.3% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 91.8% of Waters shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by insiders. Comparatively, 1.5% of Waters shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Charles River Laboratories International and Waters' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$2.62 billion6.07$252.02 million$6.7347.07
Waters$2.41 billion7.78$592.20 million$8.9933.78

Waters has lower revenue, but higher earnings than Charles River Laboratories International. Waters is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Summary

Charles River Laboratories International beats Waters on 9 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Charles River Laboratories International and Bio-Rad Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International03902.75
Bio-Rad Laboratories00303.00

Charles River Laboratories International presently has a consensus price target of $286.4167, indicating a potential downside of 9.58%. Bio-Rad Laboratories has a consensus price target of $700.00, indicating a potential upside of 19.89%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Charles River Laboratories International.

Profitability

This table compares Charles River Laboratories International and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories International10.68%22.41%7.66%
Bio-Rad Laboratories147.91%3.77%2.74%

Insider and Institutional Ownership

92.3% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Charles River Laboratories International and Bio-Rad Laboratories' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$2.62 billion6.07$252.02 million$6.7347.07
Bio-Rad Laboratories$2.31 billion7.52$1.76 billion$7.0682.70

Bio-Rad Laboratories has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.


Charles River Laboratories International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.3$454.78-2.0%$178.74 billion$25.54 billion37.28Insider Selling
Analyst Revision
Illumina logo
ILMN
Illumina
1.6$372.84-2.3%$54.43 billion$3.54 billion86.51
Agilent Technologies logo
A
Agilent Technologies
1.8$128.64-2.2%$39.20 billion$5.34 billion55.93
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,241.45-0.1%$28.89 billion$3.01 billion52.23Earnings Announcement
Waters logo
WAT
Waters
1.3$303.64-4.0%$18.73 billion$2.41 billion37.81Earnings Announcement
Analyst Report
Analyst Revision
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$583.89-2.1%$17.38 billion$2.31 billion5.00
Bio-Techne logo
TECH
Bio-Techne
1.8$408.88-1.6%$15.90 billion$738.69 million65.42Earnings Announcement
Dividend Announcement
PerkinElmer logo
PKI
PerkinElmer
1.9$137.86-1.1%$15.45 billion$2.88 billion37.46Analyst Revision
Bruker logo
BRKR
Bruker
1.7$66.45-4.1%$10.07 billion$2.07 billion65.15Analyst Revision
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$22.93-5.1%$4.55 billion$90.89 million-81.89Gap Down
Luminex logo
LMNX
Luminex
1.5$36.62-0.1%$1.73 billion$334.64 million93.90
Fluidigm logo
FLDM
Fluidigm
1.8$5.18-6.0%$388.31 million$117.24 million-7.73Earnings Announcement
Analyst Report
Gap Down
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.95-0.9%$277.70 million$116.18 million-38.61Earnings Announcement
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.85-0.0%$61.64 million$420,000.00-1.45Upcoming Earnings
Analyst Report
News Coverage
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.